Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy

Importance YARS2 mutations have been associated with a clinical triad of myopathy, lactic acidosis, and sideroblastic anemia in predominantly Middle Eastern populations. However, the identification of new patients expands the clinical and molecular spectrum of mitochondrial disorders. Objectives To review the clinical, molecular, and genetic features of YARS2-related mitochondrial disease and to demonstrate a new Scottish founder variant. Design, Setting, and Participants An observational case series study was conducted at a national diagnostic center for mitochondrial disease in Newcastle upon Tyne, England, and review of cases published in the literature. Six adults in a well-defined mitochondrial disease cohort and 11 additional cases described in the literature were identified with YARS2 variants between January 1, 2000, and January 31, 2015. Main Outcome and Measures The spectrum of clinical features and disease progression in unreported and reported patients with pathogenic YARS2 variants. Results Seventeen patients (median [interquartile range] age at onset, 1.5 [9.8] years) with YARS2-related mitochondrial myopathy were identified. Fifteen individuals (88%) exhibited an elevated blood lactate level accompanied by generalized myopathy; only 12 patients (71%) manifested with sideroblastic anemia. Hypertrophic cardiomyopathy (9 [53%]) and respiratory insufficiency (8 [47%]) were also prominent clinical features. Central nervous system involvement was rare. Muscle studies showed global cytochrome-c oxidase deficiency in all patients tested and severe, combined respiratory chain complex activity deficiencies. Microsatellite genotyping demonstrated a common founder effect shared between 3 Scottish patients with a p.Leu392Ser variant. Immunoblotting from fibroblasts and myoblasts of an affected Scottish patient showed normal YARS2 protein levels and mild respiratory chain complex defects. Yeast modeling of novel missense YARS2 variants closely correlated with the severity of clinical phenotypes. Conclusions and Relevance The p.Leu392Ser variant is likely a newly identified founder YARS2 mutation. Testing for pathogenic YARS2 variants should be considered in patients presenting with mitochondrial myopathy, characterized by exercise intolerance and muscle weakness even in the absence of sideroblastic anemia irrespective of ethnicity. Regular surveillance and early treatment for cardiomyopathy and respiratory muscle weakness is advocated because early treatment may mitigate the significant morbidity and mortality associated with this genetic disorder.

[1]  E. Pegoraro,et al.  Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations , 2016, neurogenetics.

[2]  M. Fleming,et al.  LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure. , 2015, JIMD reports.

[3]  P. Chinnery,et al.  Diagnosis of muscle diseases presenting with early respiratory failure , 2015, Journal of Neurology.

[4]  Robert W. Taylor,et al.  Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease , 2015, Annals of neurology.

[5]  M. Minczuk,et al.  Two Siblings with Homozygous Pathogenic Splice‐Site Variant in Mitochondrial Asparaginyl–tRNA Synthetase (NARS2) , 2015, Human mutation.

[6]  C. Elger,et al.  A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy , 2014, Neurology.

[7]  J. Hunter,et al.  Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encoded ATP6 gene. , 2014, Molecular genetics and metabolism.

[8]  K. McKernan,et al.  Mutation in The Nuclear‐Encoded Mitochondrial Isoleucyl–tRNA Synthetase IARS2 in Patients with Cataracts, Growth Hormone Deficiency with Short Stature, Partial Sensorineural Deafness, and Peripheral Neuropathy or with Leigh Syndrome , 2014, Human mutation.

[9]  E. Holme,et al.  Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome , 2014, Molecular genetics & genomic medicine.

[10]  A. Munnich,et al.  Unusual clinical expression and long survival of a pseudouridylate synthase (PUS1) mutation into adulthood , 2014, European Journal of Human Genetics.

[11]  Beril Talim,et al.  Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. , 2014, JAMA.

[12]  Robert W. Taylor,et al.  Distal weakness with respiratory insufficiency caused by the m.8344A > G “MERRF” mutation , 2014, Neuromuscular Disorders.

[13]  M. Minczuk,et al.  VARS2 and TARS2 Mutations in Patients with Mitochondrial Encephalomyopathies , 2014, Human mutation.

[14]  S. Jongpiputvanich,et al.  Fulminant respiratory muscle paralysis, an expanding clinical spectrum of mitochondrial A3243G tRNALeu mutation. , 2014, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[15]  K. Boycott,et al.  Compound heterozygous mutations in glycyl-tRNA synthetase are a proposed cause of systemic mitochondrial disease , 2014, BMC Medical Genetics.

[16]  N. Matsumoto,et al.  A novel homozygous YARS2 mutation causes severe myopathy, lactic acidosis, and sideroblastic anemia 2 , 2014, Journal of Human Genetics.

[17]  J. Christodoulou,et al.  Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia , 2013, Orphanet Journal of Rare Diseases.

[18]  Robert W. Taylor,et al.  Late-onset respiratory failure due to TK2 mutations causing multiple mtDNA deletions , 2013, Neurology.

[19]  Ting Wang,et al.  Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser , 2013, Bioinform..

[20]  S. Rahman,et al.  A distinct mitochondrial myopathy, lactic acidosis and sideroblastic anemia (MLASA) phenotype associates with YARS2 mutations , 2013, American journal of medical genetics. Part A.

[21]  Jørgen K. Kanters,et al.  Mitochondrial Haplogroups Modify the Risk of Developing Hypertrophic Cardiomyopathy in a Danish Population , 2013, PloS one.

[22]  T. Walsh,et al.  Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome. , 2013, American journal of human genetics.

[23]  T. Wieland,et al.  Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. , 2012, American journal of human genetics.

[24]  A. Paetau,et al.  Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. , 2012, Human molecular genetics.

[25]  Robert W. Taylor,et al.  Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management , 2012, European heart journal.

[26]  E. Shoubridge,et al.  A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia , 2012, Human mutation.

[27]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[28]  E. Bertini,et al.  Leukoencephalopathy with thalamus and brainstem involvement and high lactate 'LTBL' caused by EARS2 mutations. , 2012, Brain : a journal of neurology.

[29]  Jean-Pierre Bouchard,et al.  Mutations in the Mitochondrial Methionyl-tRNA Synthetase Cause a Neurodegenerative Phenotype in Flies and a Recessive Ataxia (ARSAL) in Humans , 2012, PLoS biology.

[30]  Matej Oresic,et al.  Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy. , 2011, American journal of human genetics.

[31]  T. Walsh,et al.  Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome , 2011, Proceedings of the National Academy of Sciences.

[32]  R. Belostotsky,et al.  Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. , 2011, American journal of human genetics.

[33]  Günther Specht,et al.  HaploGrep: a fast and reliable algorithm for automatic classification of mitochondrial DNA haplogroups , 2011, Human mutation.

[34]  F. Foury,et al.  In vivo analysis of mtDNA replication defects in yeast. , 2010, Methods.

[35]  R. Giegé,et al.  Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome. , 2010, American Journal of Human Genetics.

[36]  V. Tiranti,et al.  Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA) , 2009, BMJ Case Reports.

[37]  J. Gomori,et al.  Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. , 2007, American journal of human genetics.

[38]  R. Schiffmann,et al.  Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation , 2007, Nature Genetics.

[39]  V. Álvarez,et al.  Mitochondrial DNA haplogroups in Spanish patients with hypertrophic cardiomyopathy. , 2006, International journal of cardiology.

[40]  D. Lev,et al.  Mitochondrial Myopathy, Sideroblastic Anemia, and Lactic Acidosis: An Autosomal Recessive Syndrome in Persian Jews Caused by a Mutation in the PUS1 Gene , 2005, Journal of child neurology.

[41]  Y. Bykhovskaya,et al.  Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). , 2004, American journal of human genetics.

[42]  Robert W. Taylor,et al.  The diagnosis of mitochondrial muscle disease , 2004, Neuromuscular Disorders.

[43]  K. Casas,et al.  Mitochondrial myopathy and sideroblastic anemia , 2004, American journal of medical genetics. Part A.

[44]  D. Thorburn,et al.  Minimum birth prevalence of mitochondrial respiratory chain disorders in children. , 2003, Brain : a journal of neurology.

[45]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[46]  B. Garty,et al.  Myopathy, lactic acidosis, and sideroblastic anemia: a new syndrome. , 1995, American journal of medical genetics.

[47]  P. Philippsen,et al.  New heterologous modules for classical or PCR‐based gene disruptions in Saccharomyces cerevisiae , 1994, Yeast.

[48]  M. Labouesse,et al.  A family of low and high copy replicative, integrative and single‐stranded S. cerevisiae/E. coli shuttle vectors , 1991, Yeast.

[49]  E. Holme,et al.  Progressive Increase of the Mutated Mitochondrial DNA Fraction in Kearns-Sayre Syndrome , 1990, Pediatric Research.

[50]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[51]  P. Schimmel,et al.  An E. coli aminoacyl-tRNA synthetase can substitute for yeast mitochondrial enzyme function in vivo , 1987, Cell.

[52]  R. Hoffman,et al.  A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. , 1979, The Journal of pediatrics.

[53]  R. Weller,et al.  Familial association of metabolic myopathy, lactic acidosis and sideroblastic anemia. , 1974, The American journal of medicine.

[54]  M. Zeviani,et al.  A Novel Homozygous YARS2 Mutation in Two Italian Siblings and a Review of Literature. , 2015, JIMD reports.

[55]  Robert H Schiestl,et al.  Quick and easy yeast transformation using the LiAc/SS carrier DNA/PEG method , 2007, Nature Protocols.

[56]  Robert W. Taylor,et al.  Biochemical assays of respiratory chain complex activity. , 2007, Methods in cell biology.

[57]  E. Brett,et al.  Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. , 1991, American journal of human genetics.